SCHEMBL12005507

SCHEMBL12005507

ClCc1nnc(C2CC2)o1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 3/20 0.35
POLB P06746 1/20 0.35
KMT2A Q03164 1/20 0.35
ALOX15B O15296 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.34
HTT P42858 2/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
NOTUM Q6P988 1/20 0.33
GRIN1 Q05586 1/20 0.33
GRIN2B Q13224 1/20 0.33
CYP2C19 P33261 1/20 0.33
BRD4 O60885 2/20 0.32
PKM P14618 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
BRD2 P25440 1/20 0.31
BRD3 Q15059 1/20 0.31
BRDT Q58F21 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17582357 0.92 ALDH1A1 (0.40) ALDH1A1LMNAMAPTPOLBKMT2A
SCHEMBL11336747 0.90 ALDH1A1 (0.46) ALDH1A1LMNAMAPTPOLBKMT2A
SCHEMBL441266 0.85 HTT (0.37) ALDH1A1LMNAMAPTPOLBKMT2A
SCHEMBL408244 0.80 PKM (0.46) ALDH1A1LMNAMAPTPOLBKMT2A
SCHEMBL17629810 0.78 KMT2A (0.38) ALDH1A1MAPTPOLBKMT2AALOX15B
SCHEMBL17629752 0.78 ALDH1A1 (0.37) ALDH1A1MAPTPOLBKMT2AALOX15B
SCHEMBL12845867 0.78 ALDH1A1 (0.41) ALDH1A1MAPTPOLBKMT2AALOX15B
SCHEMBL17864242 0.78 MAPT (0.35) ALDH1A1MAPTPOLBKMT2AALOX15B
SCHEMBL5101802 0.77 USP30 (0.41) ALDH1A1LMNAMAPTKMT2AHTT
SCHEMBL16799719 0.75 AVPR1A (0.44)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119119150-B Icariside II derivative with anti-liver cancer activity and preparation method and application thereof 沈阳药科大学 2026-05-12 CN disclosed
WO-2025202922-A1 IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2025-10-02 WO disclosed
EP-4251620-B1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS CHIESI FARM SPA (IT) 2025-04-16 EP disclosed
CN-119119150-A Icariside II derivative with anti-liver cancer activity and preparation method and application thereof 沈阳药科大学 2024-12-13 CN disclosed
US-20240025880-A1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-01-25 US disclosed
WO-2023154344-A1 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-08-17 WO disclosed
US-20230045960-A1 SUBSTITUTED HETEROAROMATIC PYRAZOLO-PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2023-02-16 US disclosed
US-11530210-B2 Substituted heteroaromatic pyrazolo-pyridines and their use as GLUN2B receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2022-12-20 US disclosed
US-20220274984-A1 SUBSTITUTED HETEROAROMATIC PYRAZOLO-PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2022-09-01 US disclosed
US-11332459-B2 Benzimidazole derivatives and their uses TEIJIN PHARMA LIMITED (JP) 2022-05-17 US disclosed
WO-2016044386-A1 INDAZOLE UREAS AND METHOD OF USE ABBVIE INC. (US) 2016-03-24 WO disclosed
US-20160075692-A1 Indazole Ureas and Method of Use ABBVIE INC. (US) 2016-03-17 US disclosed
US-9045496-B2 N-substituted oxazinopteridines and oxazinopteridinones TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-06-02 US disclosed
EP-2678342-B1 N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES TAKEDA PHARMACEUTICAL (JP) 2015-01-07 EP disclosed
US-20140309219-A1 N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) 2014-10-16 US disclosed
US-8791107-B2 N-substituted oxazinopteridines and oxazinopteridinones TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-07-29 US disclosed
EP-2678342-A1 N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES Takeda Pharmaceutical Company Limited (JP) 2014-01-01 EP disclosed
CN-103384672-A N-substituted oxazinopteridines and oxazinopteridinones TAKAEDA CHEMICAL IND LTD 2013-11-06 CN disclosed
WO-2012148548-A1 N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-01 WO disclosed
US-20120220575-A1 N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230045960-A1 SUBSTITUTED HETEROAROMATIC PYRAZOLO-PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS GRIN2B, GRIN2A, GRIN2C ALDH1A1 2477/4885LMNA 4111/4885MAPT 1246/4885
US-20140309219-A1 N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES PIK3CD, PIK3CA, AKT2 ALDH1A1 895/4885LMNA 3660/4885MAPT 4718/4885
US-20220274984-A1 SUBSTITUTED HETEROAROMATIC PYRAZOLO-PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS GRIN2B, GRIN2A, GRIN2C ALDH1A1 2477/4885LMNA 4111/4885MAPT 1246/4885
US-20120220575-A1 N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES PIK3CD, PIK3CA, AKT2 ALDH1A1 895/4885LMNA 3660/4885MAPT 4718/4885
US-11530210-B2 Substituted heteroaromatic pyrazolo-pyridines and their use as GLUN2B receptor modulators GRIN2B, GRIN2A, GRIN2C ALDH1A1 2477/4885LMNA 4111/4885MAPT 1246/4885
US-20160075692-A1 Indazole Ureas and Method of Use SCN8A, SCN7A, SCN3A ALDH1A1 699/4885LMNA 1666/4885MAPT 2675/4885
US-20240025880-A1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS P2RX3, P2RX5, P2RX1 ALDH1A1 1918/4885LMNA 3348/4885MAPT 4422/4885
US-11332459-B2 Benzimidazole derivatives and their uses TRPC6, TRPV6, TRPM6 ALDH1A1 1564/4885LMNA 4022/4885MAPT 3674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.